Cat.No. : CSC-SC001231 Host Cell: HEK293 (CHO and other cell types are also available)
| Cat. No. | CSC-SC001231 |
| Description | Using Creative Biogene's proprietary lentiviral vectors, we subclone the target gene into lentivector, generate the lentivirus particles, sequentially infect the cell line HEK293 (other cell types are also available according to your requirements), and select the clones constantly expressing target gene at high level. |
| Gene | AURKA |
| Gene Species | Homo sapiens (Human) |
| Host Cell | HEK293 (CHO and other cell types are also available) |
| Stability | Validated for at least 10 passages |
| Application | 1. Gene expression studies 2. Signaling pathway research 3. Drug screening and toxicology 4. Disease research |
| Quality Control | Negative for bacteria, yeast, fungi and mycoplasma. |
| Size Form | 2 × 10^6 cells / vial |
| Shipping | Dry Ice |
| Storage | Liquid nitrogen |
| Revival | Rapidly thaw cells in a 37°C water bath. Transfer contents into a tube containing pre-warmed media. Centrifuge cells and seed into a 25 cm2 flask containing pre-warmed media. |
| Gene Name | AURKA aurora kinase A [ Homo sapiens ] |
| Gene Symbol | AURKA |
| Synonyms | AIK; ARK1; AURA; BTAK; STK6; STK7; STK15; AURORA2; PPP1R47 |
| Gene Description | aurora kinase A |
| Gene ID | 6790 |
| UniProt ID | O14965 |
| mRNA Refseq | NM_003600.2 |
| Protein Refseq | NP_003591.2 |
| Chromosome Location | 20q13 |
| Function | ATP binding; protein binding; protein kinase activity; protein kinase binding; protein serine/threonine kinase activity; protein serine/threonine/tyrosine kinase activity; ubiquitin protein ligase binding; |
| Pathway | APC/C-mediated degradation of cell cycle proteins, organism-specific biosystem; APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1, organism-specific biosystem; Aurora A signaling, organism-specific biosystem; Aurora B signaling, organism-specific biosystem; Cell Cycle, organism-specific biosystem; Cell Cycle, Mitotic, organism-specific biosystem; Integrated Breast Cancer Pathway, organism-specific biosystem; |
| MIM | 603072 |
| Mycoplasma | Negative |
| Format | One frozen vial containing millions of cells |
| Storage | Liquid nitrogen |
| Safety Considerations |
The following safety precautions should be observed. 1. Use pipette aids to prevent ingestion and keep aerosols down to a minimum. 2. No eating, drinking or smoking while handling the stable line. 3. Wash hands after handling the stable line and before leaving the lab. 4. Decontaminate work surface with disinfectant or 70% ethanol before and after working with stable cells. 5. All waste should be considered hazardous. 6. Dispose of all liquid waste after each experiment and treat with bleach. |
| Ship | Dry ice |
Bladder cancer is the most common malignant tumor of the bladder and upper urinary tract, but its clinical treatment options are limited. Aurora kinase A (AURKA) has been identified as an oncogene in cancer development and progression. However, its potential role and underlying mechanisms in bladder cancer progression remain unclear. Here, researchers evaluated the expression of Aurora kinase A (AURKA) in patient samples through gene expression profiling and found that AURKA expression levels were significantly higher in bladder cancer tissues than in normal tissues. Elevated AURKA expression in bladder cancer was closely associated with disease stage and grade. Furthermore, bladder cancer patients with elevated AURKA levels had lower overall survival rates. In vitro experiments, using gene overexpression and gene silencing methods, comprehensively validated the crucial role of AURKA in promoting bladder cancer cell proliferation. In addition, the researchers demonstrated that the AURKA inhibitor MLN8237 could inhibit bladder cancer cell growth and induce apoptosis. These findings suggest that AURKA can serve as an effective biomarker for bladder cancer detection and prognosis, as well as a potential therapeutic target.
To further verify that AURKA is a driving factor in bladder cancer cell proliferation, researchers constructed AURKA-overexpressing T24 and J82 cell lines. Western blot experiments confirmed that the expression level of AURKA in the overexpressing cells (OE) was higher than that in the untransfected control cells (WT) (Figure 1a). They assessed the differences in growth rates between control cells and AURKA-overexpressing cells at three time points during short-term culture. The results showed that the proliferation rate of AURKA-overexpressing cells was significantly increased compared to control cells (Figure 1b and c), indicating that AURKA plays an important role in promoting bladder cancer cell growth in vitro.
Figure 1. AURKA overexpression forces the proliferation of BC cells. (Guo M, et al., 2018)
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.
Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Copyright © Creative Biogene. All rights reserved.
